SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1510)3/11/1998 2:38:00 AM
From: DMB1 Recommendation  Read Replies (2) of 1762
 
Thanks for the follow up. I would have been very surprised had you found someone who would have advised Rituxan. Our thoughts and hopes are with your son for a speedy recovery after the completion of his treatments.

With regard to the immune therapy, there is a long history of immune therapy trials that have gone on at Stanford for low grade lymphomas. Their first patient, over ten years ago, did great...success has been harder to come by since.

I saw some data with regard to Rituxan that was presented at the American Society of Hematology meetings last December. The CD20 molecule, the cell surface antigen against which rituxan is directed, is a fairly large molecule. Rituxan is directed against a 5 amino acid component of that molecule. When other anti CD20 molecules were screened, 4 other molecules directed against the same 5 amino acids were identified. One of these was the antiB1 antibody used by Coulter. Of the 5 antibodies, only Rituxan could produce cell lysis in an in vitro cell cytotoxicity assay. It may be that Rituxan is working through some mechanism other than an immune mechanism. Immune therapy sounds good but it isn't the only explanation for the mechanism of action of a monoclonal antibody.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News